RIDGEFIELD, Conn. — An antiplatelet medication created by Boehringer Ingelheim is not affected when co-administered with a proton-pump inhibitor, according to results of a drug interaction study. The ...

ANI Pharmaceuticals recently introduced aspirin and extended-release dipyridamole capsules, in a dosage strength of 25mg/200mg. The product is the generic of Boehringer Ingelheim’s Aggrenox. It is ...

A drug designed to cut down on the chances of strokes in people who have suffered strokes or mini-strokes won’t be on the U.S. market in brand name form after June 11. Tuesday’s FDA drug shortage ...

New Delhi: Drug major Dr Reddy's Laboratories Monday announced the launch of anti-coagulant drug Aspirin and extended-release dipyridamole capsules in the US market. The product is a therapeutic ...

Boehringer Ingelheim and Teva Pharmaceutical Industries Ltd have agreed to pay $54 million to resolve a class action accusing them of conspiring to keep a generic version of Boehringer's stroke ...

Under Aggrenox Settlement and Supply Agreements, Barr Labs is permitted to launch an authorized generic version of Aggrenox commencing no later than July 1, 2015, approximately 18 months earlier than ...

Teva announced the launch of Aspirin and Extended-Release Dipyridamole Capsules, the generic version of Aggrenox Capsules. Teva announced the launch of Aspirin and Extended-Release Dipyridamole ...

If You Purchased Aggrenox® or Generic Aggrenox ® A Class Action Settlement Could Affect You A proposed $54 million settlement has been reached in a class action lawsuit regarding the prescription drug ...

Pharma major Dr. Reddy’s Laboratories is working towards introducing aspirin and extended-release dipyridamole capsules, a therapeutic equivalent generic version of Aggrenox capsules, in the U.S.